Amongst n = 59 patients with obesity, chronic kidney disease and type 2 diabetes, 2 (3.5%) and 0 (0%) were prescribed a GLP‐1 receptor analogue and SGLT2‐inhibitor, respectively. Here, GLP1R is linked to Obesity.